A Phase 3 interventional study of Chemotherapy (Induction Period) and Rituximab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 180 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 5th largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2011, is one of 29 in phase 3, and was the 125th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 692 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 5th largest by enrollment of the 49 interventional ones that give a count, is one of 6 that started in 2011, is one of 11 in phase 3, and was the 26th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and safety of subcutaneously administered rituximab in comparison with observation only as maintenance therapy in participants with relapsed or refractory indolent Non-Hodgkin's lymphoma (NHL). All participants will receive induction therapy with rituximab (375 milligrams per square meter [mg/m\^2] intravenously [IV] in Cycle 1, then 1400 mg subcutaneous [SC] every 3-4 weeks) plus standard chemotherapy for 6-8 months; followed by 24 months of maintenance I period with rituximab (1400 mg SC every 8 weeks). Participants completing therapy and showing partial or complete response will be randomized to receive either rituximab (1400 mg SC every 8 weeks) or observation with no treatment during maintenance II period and will be followed for at least 15 months. Anticipated time on study treatment is until disease progression, unacceptable toxicity or end of study, whichever occurs first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive standard chemotherapy regimen in combination with 375 mg/m\^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
Drug: Chemotherapy (Induction Period) · Drug: Rituximab
Participants will receive standard chemotherapy regimen in combination with 375 mg/m\^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
Drug: Chemotherapy (Induction Period) · Drug: Rituximab
Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
Participants will receive rituximab according to the regimen specified in individual arm.
Also known as: Rituxan, MabThera, RO0452294
Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Progression free survival from randomization (PFSrand) is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed. The Observation arm did not include one participant with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomization).
Time frame: From randomization (Maintenance II) up to disease progression or death, whichever occurs first (up to approximately 24 months)
Number of Participants With Adverse Events (AEs), Serious AEs, and Infusion/Administration-related Reactions (IRRs/ARRs)
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Not all AEs were followed up for the randomized Observation arm. Only Serious AEs and AE grade 3-5 (obtained retrospectively) were collected for this arm. Therefore arms are not comparable overall.
Time frame: From day of first rituximab induction dose up to day of disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)
Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Event-Free Survival was measured from the day of first rituximab Induction dose through Maintenance I and Maintenance II rituximab arm until the date of any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g. disease progression, toxicity, patient preference, initiation of new anti-lymphoma treatment, or death). Treatment discontinuation was considered as an event and was not applicable to the randomized observation arm.
Time frame: From day of first rituximab induction dose up to day of any treatment failure, including disease progression, or discontinuation of treatment for any reason (up to approximately 87 months)
Time to Next Lymphoma Treatment (TNLT)
Time to next lymphoma treatment (TNLT) is defined as the time from date of first rituximab induction dose to the date date of first documented intake of any new antilymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc.).
Time frame: From day of first rituximab induction dose up to any new lymphoma treatment (up to approximately 87 months)
Overall Survival
Overall survival from first induction treatment (OSRegist) is defined as the time from date of first rituximab induction dose to the date of death, irrespective of cause. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed.
Time frame: From day of first rituximab induction dose up to death (up to approximately 87 months)
Maintenance II: Overall Survival
Overall survival from randomization (OSrand) is defined as the time from date of randomization to the date of death, irrespective of cause.
Time frame: From randomization (Maintenance II) up to death (up to approximately 24 months)
Percentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Overall response rate is defined as the proportion of responders at the end of the Induction period. A responder is defined as a participant experiencing either CR or PR tumor response according to the Cheson response criteria for indolent lymphoma or the recommendations for Waldenström's macroglobulinemia.
Time frame: From day of first rituximab induction dose up to end of induction period (up to approximately 8 months)
Maintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Time frame: From day of first rituximab induction dose up to end of Maintenance I period (up to approximately 32 months)
Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia
Progression free survival from first induction treatment (PFSregist) is defined as the time from date of first rituximab induction dose to the date of first documented disease progression or death by any cause, whichever occurs first.
Time frame: From day of first rituximab induction dose up to disease progression or death, whichever occurs first (up to approximately 87 months)
Participants were identified for potential recruitment using pre-screening enrolment logs.
| Milestone | All Participants | Maintenance II - Arm A (Rituximab) | Maintenance II - Arm B (Observation Only) |
|---|---|---|---|
| Started | 692 | 0 | 0 |
| Completed | 494 | 0 | 0 |
| Not completed | 198 | 0 | 0 |
| Withdrew: Adverse event | 76 | 0 | 0 |
| Withdrew: Death | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 0 | 0 |
| Withdrew: Physician decision | 9 | 0 | 0 |
| Withdrew: Withdrawal by subject | 18 | 0 | 0 |
| Withdrew: Disease progression | 45 | 0 | 0 |
| Withdrew: Eligibility criteria deviation | 10 | 0 | 0 |
| Withdrew: Completed induction, no maint i received | 11 | 0 | 0 |
| Withdrew: Not responding to treatment | 11 | 0 | 0 |
| Withdrew: Termination of study in switzerland | 1 | 0 | 0 |
| Withdrew: Treated before eligibility was confirmed | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 2 | 0 | 0 |
| Withdrew: Prednisolone given prior to enrolment | 1 | 0 | 0 |
| Withdrew: Cycle 7 rituximab not given in error | 1 | 0 | 0 |
| Withdrew: Promotor request | 1 | 0 | 0 |
| Withdrew: Exceeded time limit for next cycle | 1 | 0 | 0 |
| Withdrew: Medical advisor request | 1 | 0 | 0 |
| Milestone | All Participants | Maintenance II - Arm A (Rituximab) | Maintenance II - Arm B (Observation Only) |
|---|---|---|---|
| Started | 494 | 0 | 0 |
| Completed | 276 | 0 | 0 |
| Not completed | 218 | 0 | 0 |
| Withdrew: Death | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 32 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Diseases progression | 91 | 0 | 0 |
| Withdrew: Adverse event | 70 | 0 | 0 |
| Withdrew: Physician decision | 9 | 0 | 0 |
| Withdrew: Did not meet randomization criteria | 2 | 0 | 0 |
| Withdrew: Did not perform scheduled assessment | 2 | 0 | 0 |
| Withdrew: Delay in rituximab administration | 1 | 0 | 0 |
| Withdrew: Not compliant | 1 | 0 | 0 |
| Withdrew: Did not meet criteria | 5 | 0 | 0 |
| Milestone | All Participants | Maintenance II - Arm A (Rituximab) | Maintenance II - Arm B (Observation Only) |
|---|---|---|---|
| Started | 0 | 138 | 138 |
| Completed | 0 | 115 | 111 |
| Not completed | 0 | 23 | 27 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Death | 0 | 10 | 8 |
| Withdrew: Physician decision | 0 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Moved to another town | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 9 | 8 |
| Withdrew: Changed physician in another hospital | 0 | 0 | 1 |
| Withdrew: Squamous lung carcinoma | 0 | 0 | 1 |
| Withdrew: Withdrew informed consent | 0 | 0 | 1 |
| Withdrew: Refused to be transferred to other site | 0 | 0 | 1 |
Progression free survival from randomization (PFSrand) is defined as the time from date of randomization to the date of first documented disease progression or death, whichever occurs first. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed. The Observation arm did not include one participant with AE outcome of death reported retrospectively 2 months after discontinuation from study (censored as having no event on Day 456 post-randomization).
| Months | Maintenance II - Arm A (Rituximab) | Maintenance II - Arm B (Observation Only) |
|---|---|---|
| Maintenance II: Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia | NA (NA to NA) | NA (39.75 to NA) |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Not all AEs were followed up for the randomized Observation arm. Only Serious AEs and AE grade 3-5 (obtained retrospectively) were collected for this arm. Therefore arms are not comparable overall.
| Participants | All Participants |
|---|---|
| Number of Participants with Adverse Events | 643 |
| Number of Participants with Serious Adverse Events | 339 |
| Number of Participants with IRRs/ARRs | 330 |
Event-Free Survival was measured from the day of first rituximab Induction dose through Maintenance I and Maintenance II rituximab arm until the date of any treatment failure, including disease progression, or discontinuation of treatment for any reason (e.g. disease progression, toxicity, patient preference, initiation of new anti-lymphoma treatment, or death). Treatment discontinuation was considered as an event and was not applicable to the randomized observation arm.
| Months | Maintenance II - Arm A (Rituximab) | All Participants |
|---|---|---|
| Event-free Survival (Time to Treatment Failure) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia | 65.38 (60.98 to NA) | 24.99 (20.73 to 27.99) |
Time to next lymphoma treatment (TNLT) is defined as the time from date of first rituximab induction dose to the date date of first documented intake of any new antilymphoma treatment (chemotherapy, radiotherapy, immunotherapy, etc.).
| Months | Maintenance II - Arm A (Rituximab) | Maintenance II - Arm B (Observation Only) | All Participants |
|---|---|---|---|
| Time to Next Lymphoma Treatment (TNLT) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Overall survival from first induction treatment (OSRegist) is defined as the time from date of first rituximab induction dose to the date of death, irrespective of cause. One participant died in Induction before randomization and one participant died in Maintenance II Observation arm due to an SAE and were not considered in the analysis as no death page was completed.
| Months | All Participants |
|---|---|
| Overall Survival | NA (NA to NA) |
Overall survival from randomization (OSrand) is defined as the time from date of randomization to the date of death, irrespective of cause.
| Months | Maintenance II - Arm A (Rituximab) | Maintenance II - Arm B (Observation Only) |
|---|---|---|
| Maintenance II: Overall Survival | NA (NA to NA) | NA (NA to NA) |
Overall response rate is defined as the proportion of responders at the end of the Induction period. A responder is defined as a participant experiencing either CR or PR tumor response according to the Cheson response criteria for indolent lymphoma or the recommendations for Waldenström's macroglobulinemia.
| Percentage of Participants | All Participants |
|---|---|
| Percentage of Participants With Partial or Complete Tumor Response (PR/CR) Assessment at End of Induction Using 1999 International Working Group Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia | 84.7 (81.8 to 87.3) |
| Percentage | Maintenance I |
|---|---|
| Maintenance I: Percentage of Participants With Conversion of PR to CR Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia | 21.6 (17.4 to 26.2) |
Progression free survival from first induction treatment (PFSregist) is defined as the time from date of first rituximab induction dose to the date of first documented disease progression or death by any cause, whichever occurs first.
| Months | All Participants |
|---|---|
| Progression-free Survival (PFS) Using 1999 International Working Group (Cheson) Response Criteria for Lymphoma or by the Recommendations for Waldenström's Macroglobulinemia | 59.33 (50.33 to 71.36) |
Collected over From Baseline up to 47 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | 10/138 (7.2%) | 59/138 (42.8%) | 133/138 (96.4%) |
| Arm B (Observation Only) | 8/138 (5.8%) | 58/138 (42%) | 133/138 (96.4%) |
| All Participants | 161/692 (23.3%) | 339/692 (49%) | 643/692 (92.9%) |
| Event | Arm A | Arm B (Observation Only) | All Participants |
|---|---|---|---|
| PneumoniaInfections and infestations | 14/138 | 6/138 | 54/692 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/138 | 2/138 | 36/692 |
| NeutropeniaBlood and lymphatic system disorders | 1/138 | 6/138 | 22/692 |
| Lower respiratory tract infectionInfections and infestations | 1/138 | 5/138 | 10/692 |
| Lung infectionInfections and infestations | 2/138 | 4/138 | 7/692 |
| BronchitisInfections and infestations | 0/138 | 4/138 | 5/692 |
| SepsisInfections and infestations | 3/138 | 2/138 | 18/692 |
| Acute kidney injuryRenal and urinary disorders | 0/138 | 3/138 | 6/692 |
| Infusion related reactionInjury, poisoning and procedural complications | 3/138 | 0/138 | 7/692 |
| Urinary tract infectionInfections and infestations | 3/138 | 2/138 | 12/692 |
| Event | Arm A | Arm B (Observation Only) | All Participants |
|---|---|---|---|
| MeningitisInfections and infestations | 0/138 | 0/138 | 1/1 |
| NeutropeniaBlood and lymphatic system disorders | 48/138 | 51/138 | 226/692 |
| CoughRespiratory, thoracic and mediastinal disorders | 47/138 | 24/138 | 135/692 |
| NauseaGastrointestinal disorders | 45/138 | 37/138 | 199/692 |
| DiarrhoeaGastrointestinal disorders | 35/138 | 28/138 | 143/692 |
| PyrexiaGeneral disorders | 32/138 | 29/138 | 159/692 |
| FatigueGeneral disorders | 30/138 | 19/138 | 115/692 |
| Neutrophil count decreasedInvestigations | 28/138 | 29/138 | 113/692 |
| NasopharyngitisInfections and infestations | 29/138 | 24/138 | 72/692 |
| AstheniaGeneral disorders | 27/138 | 19/138 | 113/692 |
The Intent-to-Treat (ITT) population was used for the analysis of secondary efficacy parameters and Baseline variables. The randomised ITT population (ITTrand) included only randomised participants of Maintenance II period and was used for the analysis of the primary efficacy endpoint of PFS and the secondary analysis endpoint overall survival (OS)
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 64.6 ± 11.14 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 346 |
| Male | 346 |
| Race/Ethnicity, Customized(Participants) | All Participants |
|---|---|
| Caucasian | 579 |
| Black | 7 |
| Asian | 5 |
| Other | 32 |
| Not applicable as per local regulation | 69 |
Showing the first 100 of 180 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2011 to primary completion in Jun 2018, 77 months.
Results were first posted in Aug 2019, 1 year 2 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 77 months is above that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab